TMS Co.,Ltd.

ティムス is a listed company focused primarily on pharmaceutical development. It is expanding its pipeline through a two-pronged approach involving in-house and external programs. The company is advancing global clinical development centered on TMS-007 (JX10) and continuing related activities involving TMS-008, TMS-009/JX-09, TMS-010 and other programs. In January 2026, it completed patent applications for a group of 100 novel compounds, and subject enrollment began in Japan. Under a license agreement with Hokkaido University, TMS-010 was added to the pipeline, and the company holds rights related to the exclusive development and commercialization rights involving CORXEL Pharmaceuticals Hong Kong Limited. As an external program, the company continues to examine the potential applications of novel stable analogs of the bioactive lipid resolvin introduced from Hokkaido University. In 2026, it is advancing pipeline expansion through multiple approaches, including AI-based design and screening of natural-product libraries. Financially, the company recorded R&D expenses of ¥239.806 million and SG&A expenses of ¥152.455 million. Total operating expenses were ¥392.262 million, operating loss was ¥392.262 million, ordinary loss was ¥392.479 million, and interim net loss was ¥393.538 million. Cash and cash equivalents at period-end were ¥2,459.128 million. The total number of shares issued increased to 46,341,767 following the exercise of stock acquisition rights, resulting in changes in capital stock and capital reserves (exercise period: 2026-05-13–2041-05-12; issue price: ¥146.18; amount paid in: ¥1).